Brooke Peters, PharmD, BCOP

Brooke Peters, PharmD, BCOP, offers a closing reflection on the transition from inpatient to outpatient treatment of bispecific antibodies.

A discussion on the evolving practices for administering bispecific T-cell engagers, from academic to community centers.

Dr. Peters shares clinical considerations for administering bispecifics, emphasizing the identification and mitigation strategies of late adverse events.

Expert regional community oncologist examines the grading and management of early adverse events such as CRS and ICANS, discussing the national guidelines that are utilized.

Expanding on the roles and responsibilities for executing a bispecifics administration program, highlighting a multidisciplinary collaboration to establish SOPs, training, and education.

Dr. Peters shares her experience in SOPs and program development for administration of bispecific T-cell engagers, noting program champions and key program components.

Brooke Peters, PharmD, BCOP, provides a comprehensive overview of her institution’s bispecifics administration program, highlighting several agents and the hematologic/oncologic conditions they treat.